Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Calgary

$27,000.00

Targeting TNFRSF-Signalling in Monocytes to Enhance Vaccine-Mediated Protective Immunity

FY 2025-26

Summary
Leishmaniasis is a serious disease caused by a parasite that affects millions of people worldwide. It can cause severe skin ulcers and life-threatening infections of the liver and spleen. The parasites are difficult for the body to eliminate because they survive and replicate inside of immune cells called monocytes. However, people who recover from leishmaniasis become extremely resistant to getting sick again, meaning their immune system has learned how to control the parasite if it returns. This strong, long-lasting protection is what scientists aim to achieve with a vaccine, but despite many attempts, no vaccine has been able to successfully reproduce it. During a second infection, the immune system responds quickly through cells called T helper 1 (Th1)-cells. However, recent observations suggest completely clearing the parasite requires a second, slower phase that continues for weeks, and this stage is not understood. A major gap in knowledge is how infected monocytes communicate with Th1 cells to keep the immune response active over this later stage. This project will investigate a newly proposed communication pathway, called ‘signal 4’, where molecules on monocytes provide critical support signals to Th1 cells. Early findings from our lab show that this pathway is strongly activated during protective immunity. This research will test how monocytes and Th1 cells use signal 4 to maintain this second stage of parasite control. Understanding this process will reveal how the immune system naturally achieves durable protection, and why vaccines have struggled to replicate it. These insights may guide new therapies or vaccine strategies for leishmaniasis and for other infections such as tuberculosis, that operate in similar ways.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572691
Name
Huska Hanna H
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting TNFRSF-Signalling in Monocytes to Enhance Vaccine-Mediated Protective Immunity
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cd4+ T Cells; Immune Memory; Immunology; Infectious Diseases; Inflammation; Leishmania; Monocytes; T Helper 1 Immunity; Tumor Necrosis Factor Receptor Superfamily; Vaccination
Abstract
Leishmaniasis is a serious disease caused by a parasite that affects millions of people worldwide. It can cause severe skin ulcers and life-threatening infections of the liver and spleen. The parasites are difficult for the body to eliminate because they survive and replicate inside of immune cells called monocytes. However, people who recover from leishmaniasis become extremely resistant to getting sick again, meaning their immune system has learned how to control the parasite if it returns. This strong, long-lasting protection is what scientists aim to achieve with a vaccine, but despite many attempts, no vaccine has been able to successfully reproduce it. During a second infection, the immune system responds quickly through cells called T helper 1 (Th1)-cells. However, recent observations suggest completely clearing the parasite requires a second, slower phase that continues for weeks, and this stage is not understood. A major gap in knowledge is how infected monocytes communicate with Th1 cells to keep the immune response active over this later stage. This project will investigate a newly proposed communication pathway, called ‘signal 4’, where molecules on monocytes provide critical support signals to Th1 cells. Early findings from our lab show that this pathway is strongly activated during protective immunity. This research will test how monocytes and Th1 cells use signal 4 to maintain this second stage of parasite control. Understanding this process will reveal how the immune system naturally achieves durable protection, and why vaccines have struggled to replicate it. These insights may guide new therapies or vaccine strategies for leishmaniasis and for other infections such as tuberculosis, that operate in similar ways.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Huska, Hanna H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~